Q1 2022 Results

Company overview Financial performance Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials References Abbreviations Net debt increased by USD 9.8bn mainly due to the annual dividend payment and share buybacks (USD bn) -0.9 -7.5 -0.8 -9.8 -10.7 Dec 31, 2021 Dividends M&A transactions -2.4 Treasury share transactions, net 0.9 Free Cash Flow Mar 31, 2022 30 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation